Description
| Description | KR-33493 is a FAS-associated factor 1 (FAF1) inhibitor and can be used in studies about Parkinson’s disease. |
| In vitro | Bodyweight changes of both sexes are not related to KR-33493 in all doses. In rats administrated KR-33493 for 4 weeks, no test article-related changes in any treated groups of either sex are found in hematology, serum biochemistry, and urinalysis. In dogs administrated KR-33493 for 2 weeks, red blood cell count (RBC) value in males is significantly higher at the 1000 mg/kg/day dose than that of the control group (i.e., 6.96±0.323 vs. 6.12±0.418). However, the change of RBC is recovered after the end of the administration period. |
| In vivo | In Sprague-Dawley (SD) rats, KR-33493(500 and 1000 mg/kg; oral) shows no significant changes including Bodyweight changes, hematology, serum biochemistry, and urinalysis. In dogs, red blood cell count value in males is significantly higher at the 1000 mg/kg/day dose with KR-33493 and is recovered after the end of the administration period[1]. |
| Synonyms | KR-33494 |
| Molecular Weight |
460.34 |
| Formula | C20H18BrN3O3S |
| CAS No. | 1021497-97-1 |
Storage
store under nitrogen
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
Solubility Information
DMSO: 28 mg/mL (60.8 mM)
( < 1 mg/ml refers to the product slightly soluble or insoluble )
